Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Frontera Approved to Start China Trial of Gene Therapy for Inherited Retinal Degeneration

publication date: Sep 21, 2022

Frontera Therapeutics, a US-China gene therapy company, announced its lead candidate was approved to start China trials, targeting inherited retinal degenerations with a RPE65 mutation, a rare disease. FT-001 is an AAV gene therapy candidate administered by a one-time injection into the subretinal space of the eye to deliver a functional copy of the human RPE65 gene to the nuclei ofretinal cells. The injection causes the expression of functional RPE65 proteins, improving a patient’s vision. In April, FT-001 was approved to start US trials. Frontera is headquartered in the Boston area with operations also in Suzhou. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China